Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification.

Anand P, Elsafa E, Privitera R, Naidoo K, Yiangou Y, Donatien P, Gabra H, Wasan H, Kenny L, Rahemtulla A, Misra P.

J Pain Res. 2019 Jul 3;12:2039-2052. doi: 10.2147/JPR.S213912. eCollection 2019.

2.

Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.

Beckerson J, Szydlo RM, Hickson M, Mactier CE, Innes AJ, Gabriel IH, Palanicawandar R, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlu J.

Clin Nutr. 2019 Apr;38(2):738-744. doi: 10.1016/j.clnu.2018.03.008. Epub 2018 Mar 28.

3.

Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.

Pavlů J, Auner HW, Szydlo RM, Sevillano B, Palani R, O'Boyle F, Chaidos A, Jakob C, Kanfer E, MacDonald D, Milojkovic D, Rahemtulla A, Bradshaw A, Olavarria E, Apperley JF, Pello OM.

Bone Marrow Transplant. 2017 Dec;52(12):1599-1601. doi: 10.1038/bmt.2017.113. Epub 2017 Jun 26.

4.

C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality.

Patel A, Szydlo RM, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, Altaf S, Innes A, Gabriel I, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlů J.

Br J Haematol. 2018 Mar;180(6):889-892. doi: 10.1111/bjh.14454. Epub 2016 Nov 29. No abstract available.

5.

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.

Spanoudakis E, Papoutselis M, Terpos E, Dimopoulos MA, Tsatalas C, Margaritis D, Rahemtulla A, Kotsianidis I, Karadimitris A.

Blood Cancer J. 2016 Nov 11;6(11):e500. doi: 10.1038/bcj.2016.108. No abstract available.

6.

Pulse oximetry error in a patient with a Santa Ana haemoglobinopathy.

Robertson A, Rahemtulla A.

BMJ Case Rep. 2016 Sep 6;2016. pii: bcr2016216787. doi: 10.1136/bcr-2016-216787.

7.

Correlation of multiparameter flow cytometry and bone marrow trephine immunohistochemistry in the identification and characterization of neoplastic plasma cells.

Menter T, Abdulsalam AH, Nadal-Melsio E, Yebra-Fernandez E, Flora RS, Ahmad R, Rahemtulla A, Naresh KN.

Br J Haematol. 2017 Nov;179(3):499-501. doi: 10.1111/bjh.14223. Epub 2016 Jul 5. No abstract available.

PMID:
27378518
8.

Hodgkin's lymphoma (relapsed or refractory): autologous stem cell therapy.

Rahemtulla A, Terpos E.

BMJ Clin Evid. 2015 Oct 26;2015. pii: 2404. Review.

9.

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Ersek A, Xu K, Antonopoulos A, Butters TD, Santo AE, Vattakuzhi Y, Williams LM, Goudevenou K, Danks L, Freidin A, Spanoudakis E, Parry S, Papaioannou M, Hatjiharissi E, Chaidos A, Alonzi DS, Twigg G, Hu M, Dwek RA, Haslam SM, Roberts I, Dell A, Rahemtulla A, Horwood NJ, Karadimitris A.

J Clin Invest. 2015 Jun;125(6):2279-92. doi: 10.1172/JCI59987. Epub 2015 Apr 27.

10.

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.

Parrish C, Rahemtulla A, Cavet J, Pearce RM, Kirkland K, Lee J, Cook M, Wilson K, Cook G; Clinical Trials Committee of the British Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1330-4. doi: 10.1016/j.bbmt.2015.03.026. Epub 2015 Apr 3.

11.

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors.

Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura AK, Dyson J, Walker BA, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G.

Cancer Cell. 2014 Dec 8;26(6):938. doi: 10.1016/j.ccell.2014.11.021. Epub 2014 Dec 8. No abstract available.

12.

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.

Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura AK, Dyson J, Walker BA, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G.

Cancer Cell. 2014 Oct 13;26(4):495-508. doi: 10.1016/j.ccr.2014.07.027. Erratum in: Cancer Cell. 2014 Dec 8;26(6):938.

13.

Nuclear proteasomes carry a constitutive posttranslational modification which derails SDS-PAGE (but not CTAB-PAGE).

Pitcher DS, de Mattos-Shipley K, Wang Z, Tzortzis K, Goudevenou K, Flynn H, Bohn G, Rahemtulla A, Roberts I, Snijders AP, Karadimitris A, Kleijnen MF.

Biochim Biophys Acta. 2014 Dec;1844(12):2222-8. doi: 10.1016/j.bbapap.2014.08.013. Epub 2014 Sep 2.

14.

Azurophilic granules in myeloma cells.

Bain BJ, Siow W, Rahemtulla A, Abdalla S.

Am J Hematol. 2014 Apr;89(4):437. doi: 10.1002/ajh.23651. Epub 2014 Jan 21. No abstract available.

15.

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A.

Blood. 2014 Jan 30;123(5):697-705. doi: 10.1182/blood-2013-01-478420. Epub 2013 Dec 13.

16.

Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.

Auner HW, Moody AM, Ward TH, Kraus M, Milan E, May P, Chaidos A, Driessen C, Cenci S, Dazzi F, Rahemtulla A, Apperley JF, Karadimitris A, Dillon N.

PLoS One. 2013 Sep 17;8(9):e74415. doi: 10.1371/journal.pone.0074415. eCollection 2013.

17.

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.

Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, MacDonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K.

Bone Marrow Transplant. 2013 Oct;48(10):1324-8. doi: 10.1038/bmt.2013.69. Epub 2013 May 20.

PMID:
23686098
18.

Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy.

Patel A, Waheed U, Brett SJ, Rahemtulla A, Apperley JF, Patel PB.

Leuk Lymphoma. 2014 Jan;55(1):198-200. doi: 10.3109/10428194.2013.794266. Epub 2013 May 15. No abstract available.

PMID:
23573827
19.

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.

Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E, Macdonald DH, Marin D, Milojkovic D, Pavlu J, Apperley JF, Rahemtulla A.

Leuk Lymphoma. 2013 Oct;54(10):2200-4. doi: 10.3109/10428194.2013.773998. Epub 2013 Mar 4.

PMID:
23387937
20.

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.

Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M, Harrington H, Doolittle H, Terpos E, Dimopoulos M, Abdalla S, Yarranton H, Naresh K, Foroni L, Reid A, Rahemtulla A, Stumpf M, Roberts I, Karadimitris A.

Blood. 2013 Jan 10;121(2):318-28. doi: 10.1182/blood-2012-06-436220. Epub 2012 Nov 20.

21.

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.

Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S, Bubici C.

Oncogene. 2013 Sep 5;32(36):4231-42. doi: 10.1038/onc.2012.448. Epub 2012 Oct 8.

22.

Variable performance of commercial epidermal growth factor receptor antibodies in detection of basal-like breast cancer.

Won JR, Gao D, Grant D, Cupples J, Rahemtulla A, Wolber R, Nielsen TO, Gilks CB.

Histopathology. 2012 Sep;61(3):518-9. doi: 10.1111/j.1365-2559.2012.04262.x. Epub 2012 May 29. No abstract available.

PMID:
22642766
23.

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A.

Blood. 2012 May 24;119(21):5030-6. doi: 10.1182/blood-2011-11-389304. Epub 2012 Feb 27.

24.

Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.

Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A.

Br J Haematol. 2012 Apr;157(1):125-7. doi: 10.1111/j.1365-2141.2011.08906.x. Epub 2011 Nov 3. No abstract available.

PMID:
22050411
25.

EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure.

Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo R.

Biol Blood Marrow Transplant. 2012 Feb;18(2):235-40. doi: 10.1016/j.bbmt.2011.06.010. Epub 2011 Jun 30.

26.

Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.

Cook G, Liakopoulou E, Pearce R, Cavet J, Morgan GJ, Kirkland K, Lee J, Davies FE, Hall R, Rahemtulla A, Russell N, Marks DI; British Society of Blood & Marrow Transplantation Clinical Trials Committee.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1638-45. doi: 10.1016/j.bbmt.2011.04.005. Epub 2011 Apr 23.

27.

Excess bone marrow B-cells in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation is a biomarker for improved survival.

Byrne E, Naresh KN, Giles C, Rahemtulla A.

Br J Haematol. 2011 Nov;155(4):509-11. doi: 10.1111/j.1365-2141.2011.08700.x. Epub 2011 May 3. No abstract available.

PMID:
21539533
28.
29.

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J.

Bone Marrow Transplant. 2012 Jan;47(1):18-23. doi: 10.1038/bmt.2011.9. Epub 2011 Feb 28.

PMID:
21358693
30.

Bone marrow aspirate and trephine biopsy findings in lymphoplasmacytic lymphoma.

Naresh KN, Trivedi P, Luqmani A, Rahemtulla A.

Am J Hematol. 2011 Mar;86(3):311-2. doi: 10.1002/ajh.21925. Epub 2011 Feb 15. No abstract available.

31.

Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.

Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K.

Biol Blood Marrow Transplant. 2011 May;17(5):632-9. doi: 10.1016/j.bbmt.2010.08.002. Epub 2010 Aug 11.

32.

LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre.

Pavlů J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, Rahemtulla A, Apperley JF, Naresh K, MacDonald DH, Kanfer EJ.

Hematol Oncol. 2011 Jun;29(2):75-80. doi: 10.1002/hon.956. Epub 2010 Jul 14.

PMID:
20635327
33.

Percutaneous vertebroplasty to treat painful myelomatous vertebral deposits-long-term efficacy outcomes.

Garland P, Gishen P, Rahemtulla A.

Ann Hematol. 2011 Jan;90(1):95-100. doi: 10.1007/s00277-010-1021-2. Epub 2010 Jul 6.

PMID:
20607538
34.

High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.

Auner HW, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, Bua M, Giles C, Apperley JF, Rahemtulla A.

Bone Marrow Transplant. 2011 Mar;46(3):364-7. doi: 10.1038/bmt.2010.141. Epub 2010 Jun 21.

PMID:
20562926
35.

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.

Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K.

Blood. 2010 Sep 23;116(12):2033-9. doi: 10.1182/blood-2010-03-273706. Epub 2010 Jun 18.

36.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Pavlů J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM.

Blood. 2010 May 20;115(20):4018-20. doi: 10.1182/blood-2010-01-263624. Epub 2010 Mar 19.

37.

The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome.

Ngo NT, Brodie C, Giles C, Horncastle D, Klammer M, Lampert IA, Rahemtulla A, Naresh KN.

J Clin Pathol. 2009 Nov;62(11):1009-15. doi: 10.1136/jcp.2009.065128.

PMID:
19861559
38.

Immunophenotype of neoplastic plasma cells in AL amyloidosis.

Deshmukh M, Elderfield K, Rahemtulla A, Naresh KN.

J Clin Pathol. 2009 Aug;62(8):724-30. doi: 10.1136/jcp.2009.065474.

PMID:
19638544
39.

Hodgkin's lymphoma.

Rahemtulla A, Terpos E.

BMJ Clin Evid. 2009 Jun 15;2009. pii: 2404. Review.

40.

Regulation of multiple myeloma survival and progression by CD1d.

Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A, Kotsianidis I, Abdalla S, Rahemtulla A, Karadimitris A.

Blood. 2009 Mar 12;113(11):2498-507. doi: 10.1182/blood-2008-06-161281. Epub 2008 Dec 3.

41.
42.

Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.

Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN.

J Clin Pathol. 2008 Feb;61(2):213-6. Epub 2007 May 25.

PMID:
17526802
43.

Multiple myeloma with bone marrow extracellular crystal deposition.

Brodie C, Agrawal S, Rahemtulla A, O'Shea D, Lampert I, Naresh KN.

J Clin Pathol. 2007 Sep;60(9):1064-5. Epub 2007 May 11. No abstract available.

44.

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.

Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E, Bua M, Rahemtulla A, Kanfer E, Marin D, Olavarria E, Goldman JM, Apperley JF, Dazzi F.

Leukemia. 2007 May;21(5):943-8. Epub 2007 Mar 15.

PMID:
17361226
45.

Images in cardiovascular medicine. Intermittent loss of second heart sound.

Joshi J, Wechalekar AD, Bourdillon PJ, Joshi RP, Rahemtulla A, Hawkins PN.

Circulation. 2006 Nov 28;114(22):e612-3. No abstract available.

PMID:
17130350
46.

LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.

Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.

Bone Marrow Transplant. 2007 Jan;39(1):41-7. Epub 2006 Nov 20.

PMID:
17115062
47.

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.

Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.

Br J Haematol. 2006 Dec;135(5):688-92.

PMID:
17107351
48.

Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation.

Perz JB, Kristen AV, Rahemtulla A, Parameshwar J, Sack FU, Apperley JF, Goldschmidt H, Katus HA, Dengler TJ.

Clin Res Cardiol. 2006 Dec;95(12):671-4. Epub 2006 Sep 14. No abstract available.

PMID:
16967191
49.

The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.

Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI; British Society of Blood and Marrow Transplantation.

Br J Haematol. 2006 Aug;134(4):385-90. Epub 2006 Jul 5.

PMID:
16822294
50.

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation.

Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E.

Int J Cancer. 2006 Oct 1;119(7):1728-31.

Supplemental Content

Loading ...
Support Center